Vivus Inc. (VVUS) 1.10 $VVUS Biotechnology Equities

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 9:08 PM

Vivus Inc. (VVUS) 1.10 $VVUS

Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 4.78 (+0.12), BIIB: 238.62 (+4.02), VVUS: 1.10 (unch), PTCT: 7.00 (+0.40)

Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 0.50 (+0.04), RTRX: 18.49 (+0.01), VVUS: 1.10 (unch), ARNA: 1.91 (+0.06)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of VIVUS Inc. - VVUS
PR Newswire - Tue May 17, 10:31AM CDT
Levi & Korsinsky announces it has commenced an investigation of VIVUS Inc. (NASDAQ: VVUS) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
VVUS: 1.10 (unch)

Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Mon May 16, 11:53AM CDT
Purcell Julie & Lefkowitz LLP, a securities class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of VIVUS, Inc. (NASDAQ: VVUS). On April 22, 2016, VIVUS's stock price closed at $1.80 per share. On May 3, 2016, VIVUS announced that its revenue for the first quarter of 2016 was $15.3 million, far less than the $32.2 million in revenue for the first quarter of 2015. VIVUS's stock price closed at $1.16 per share on May 13, 2016.
VVUS: 1.10 (unch)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.39 (+0.06), INO: 9.85 (-0.35), VVUS: 1.10 (unch), TEVA: 51.37 (+0.18), ARNA: 1.91 (+0.06), PBYI: 33.65 (+2.12)

Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 5.36 (+0.11), JAZZ: 145.00 (+2.06), VVUS: 1.10 (unch), ARNA: 1.91 (+0.06)

Vivus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Vivus Inc. (VVUS) on Tuesday reported a loss of $12.7 million in its first quarter.
VVUS: 1.10 (unch)

Vivus Reports 2016 First Quarter Financial Results
Marketwired - Tue May 03, 3:05PM CDT
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"

, a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2016. The net loss for the 2016 first quarter was $12.7 million as compared to $15.5 million in 2015. Cash, cash equivalents and available-for-sale securities was $227.8 million at March 31, 2016.
VVUS: 1.10 (unch)

VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference
Marketwired - Tue Apr 19, 5:01PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2016 after the NASDAQ Market closes on Tuesday, May 3, 2016. The company will conduct a conference call and an audio webcast at 4:30 pm EST the same day.
VVUS: 1.10 (unch)

Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.14 (+0.06), VVUS: 1.10 (unch), PETX: 6.24 (+0.27), GALE: 2.15 (-0.12)

VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:05AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
VVUS: 1.10 (unch)

Stocks to Trade: Those Looking Can Consider This List
ACCESSWIRE - Thu Mar 31, 10:59AM CDT
MIAMI, FL / ACCESSWIRE / March 31, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. VVUS, COOL, SKYS, and GNCA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
COOL: 0.80 (+0.01), SKYS: 3.12 (-0.02), VVUS: 1.10 (unch), GNCA: 4.67 (+0.98)

Support.com Appoints Lowell Robinson and Elizabeth Fetter to Board of Directors
BusinessWire - Tue Mar 15, 7:00AM CDT
Support.com, Inc. (NASDAQ:SPRT), makers of award-winning, cloud-based Nexus(R) software for Support Interaction Optimization (SIO) and a leading provider of tech support and turnkey support center services, today announced the appointment of Lowell Robinson and Elizabeth Fetter, both highly regarded and accomplished business executives with substantial public company board experience, to its Board as new independent directors, effective immediately.
YHOO: 37.78 (+0.42), IKAN: 2.74 (unch), ONE: 3.73 (+0.22), QTM: 0.46 (+0.04), MGRC: 30.79 (+1.15), SPRT: 0.78 (-0.01), C: 44.46 (+1.78), VVUS: 1.10 (unch), EVLV: 1.79 (+0.04)

VIVUS Posts Narrower Loss in Q4 but Misses on Revenues
Arpita Dutt - Zacks Investment Research - Thu Mar 10, 8:10AM CST
VIVUS (VVUS) continues to face challenges in the branded obesity market.
ADRO: 10.93 (+0.70), VVUS: 1.10 (unch), SNY: 41.19 (+0.90)

VIVUS Reports Fourth Quarter and Year-End 2015 Financial Results
Marketwired - Wed Mar 09, 3:15PM CST
VIVUS, Inc. (NASDAQ: VVUS) (the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Core Lab's Quarterly Grit: Navigating a Turbulent Market

Core Lab's Quarter in Review With the kind of resilience that makes a trader's hands shake ever so slightly less over a coffee, Core Laboratories Inc. heads into the fourth quarter of 2026. This isn't your typical Wall Street story, that's for sure. Watching a solid player like Core navigate the bumpy roads of today's volatile market reminds me of a...

AST SpaceMobile Suit Seeks Lead Plaintiff by November 13

The Legal Rigmarole The market's got its knickers in a twist over AST SpaceMobile, folks. If you've been dabbling in NASDAQ:ASTS between March '25 and mid-July '26, it's time to perk up those ears. The legal eagles at Robbins Geller Rudman & Dowd LLP are rallying the troops for a class action lawsuit with you front and center. Deadline's looming on November 13, 2026, for...

Huron Consulting Joins S&P SmallCap 600 Lineup Soon

Shuffling the Deck: Huron Consulting Steps In Just when you thought the index shuffle was settled, along comes an eleventh-hour change. Huron Consulting Group is being welcomed with open arms into the S&P SmallCap 600, booting Supernus Pharmaceuticals to the side. Mark November 3 on your calendars—final scorecards before the trading bell could surprise us all. The S&P...

Psoriasis Shines Spotlight on Stigma in 2026 Campaign

Peeling Back the Layers of Stigma On World Psoriasis Day, we're flipping the script from pity parties to real change. IFPA's 'Look Beyond My Skin' campaign is rallying against the stigma choking young folks with psoriasis. You can't deny the massive size of this issue – over 100 million people wrangle with this condition globally. Yet, as many of these warriors are...

Guidewire's 2026 Awards Highlight AI in Insurance Shift

AI Takes Center Stage at Guidewire's Annual Gala Change is constant, but when it comes with a potent mix of AI and insurance, you know things are about to get interesting. Guidewire Software (NYSE: GWRE) is tipping its hat to Beazley, Definity, and RCIS, the standouts at its annual Innovation Awards. Held during their CONNECTIONS Conference in Las Vegas, this year's...

Medunik USA Ensures Steady Supply of Pheburane Amid Changes

There's a breath of relief in the air over at Medunik USA, where they're keeping a steady course amidst some choppy waters. Those dealing with urea cycle disorders (UCD) have had their fair share of ups and downs, but Pheburane® isn’t going anywhere anytime soon. Medunik USA Holds the Line So, picture yourself in the shoes of a patient battling a rare urea cycle...

Jamaica's Tourism Rebounds Post-Hurricane Challenges

Weathering the Storm: A New Chapter for Jamaica It's been nearly a year since Hurricane Melissa hit, and Jamaica is proving that it won't be pushed around by nature's whims. The island's tourism industry, once battered, is now showing remarkable resilience. With hotels and villas reopening and shaking off the dust, it's safe to say Jamaica is back on its feet, and it's...

Corgi Revamps Malpractice Insurance for Healthcare Sector

Streamlining Insurance for Healthcare Professionals Here's one for the books in the insurance world: Corgi Insurance is stepping up to spare healthcare practices from the headache of getting medical malpractice coverage. This is more than just insurance talk; it's about time someone carved out a path through the labyrinth of medical malpractice policies. Healthcare folks...

Veterinary Implants Market to Hit $0.98B by 2031

Veterinary Implants Market: A Growth Tale Something's stirring in the veterinary world, my friend. The Veterinary Implants Devices Market is hitting some serious strides, and we're looking at a valuation touching nearly $0.98 billion by 2031. If you're eyeing the veterinary sector, it's time to sharpen those pencils and take notes on where the trend winds are blowing....

MidCap Financial Faces Scrutiny Amid Ares Capital Merger

MidCap Financial's Merger Sparks Legal Action Nobody expects their investments to end up in a courtroom drama, but here we are. MidCap Financial Investment Corporation (NASDAQ: MFIC) is under the microscope, thanks to attorney Juan Monteverde's M&A Class Action Firm. From their perch in the Empire State Building, Monteverde & Associates, celebrated as a top dog in the ISS...